Prostatype Genomics Investor Relations Material

Prostatype Genomics AB specializes in developing, manufacturing, and marketing the Prostatype genetic test, which assesses the aggressiveness of prostate cancer. The test aids clinicians and patients in making informed treatment decisions by minimizing both over- and under-treatment, thereby improving patient quality of life and optimizing healthcare resources. The Prostatype test uses genetic expression data from prostate biopsies combined with clinical parameters to predict cancer prognosis. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.